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Introduction
Conventional plasmid vectors (pDNA) possess unwanted
prokaryotic DNA that when delivered to the mammalian
cells can reduce transgene expression and integrate into the
human genome, potentiating oncogenesis. Bacterial
sequence-free, linear covalently closed (LCC) DNA mini-
vectors have shown improved safety and efficacy both in
vitro and in vivo. We previously constructed and character-
ized an in vivo LCC DNA minivector (ministring) system
that can convert pDNA into DNA ministrings. Here we
sought to optimize this system and apply ministrings to
encode a gene to generate HIV virus-like particles (VLPs)
in targeted cells. The DNA-VLP expresses gagV3(BCE)
gene in target cells to simultaneously yield GagV3(BCE)
VLP assembly and presentation of immunodominant HIV
antigens, eliciting production of neutralizing antibodies and
cytotoxic T-cell responses against HIV.
Methods
A one-step invivo linear covalently closed (LCC) mini-
plasmid production system that conditionally expresses
the tel protelomerase was constructed in Ecoli (R-cells) to
enable efficient production of DNA ministrings from a
specialized pDNA. LCC gagV3(BCE) DNA ministrings
were produced from the constructed precursor pGagV3
(BCE) parent plasmid (from Dr. Chil-Yong Kang) when
passaged through R-cells. Protease gene deletions were
introduced into R-cells to sustain protelomerase expres-
sion while limiting the detrimental effects of heat shock-
induced recombinant protein degradation upon prolonged
heat induction. Plasmid and DNA ministring derivatives
were lipoplexed with a RGD-complexed gemini surfactant
and transfected into immortalized leukemia K562 cells
with induced surface expression of CD51/CD61, and
assessed for cell trafficking, transfection efficiency and
viability.
Results
R-cells with a hflX protease-associated gene deletion sig-
nificantly imcreased DNA gagV3(BCE) DNA ministring
yields to greater than 90%, compared to ~70% in wildtype
cells. DNA ministrings indicated remarkably improved cel-
lular trafficking and nuclear translocation of the vector,
significantly higher transfection rates and LCC DNA
proved far safer than the circular pDNA, where cells hav-
ing undergone unwanted vector integration events into
were targeted for cell death.
Conclusion
We optimized a robust technology conferring one-step
in vivo production of an efficient and safe DNA minis-
tring gagV3(BCE) DNA-VLP vaccine gene therapeutic
versus HIV.
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